



NDA 212315
NADA N-141-505

**DEEMED GRANTED -
MEDICAL GAS CERTIFICATION REQUEST**

Universal Industrial Gases, Inc.
Attention: Todd A. Jackson, Operations Manager
3001 Emrick Blvd., Suite 320
Bethlehem, PA 18020-8041

Dear Mr. Jackson:

Please refer to your June 19, 2018, request, received on June 25, 2018, for certification of Nitrogen, NF, as a designated medical gas. You have requested to market Nitrogen, NF, for both human and animal drug use.

A request for certification of a medical gas as a designated medical gas submitted under section 575(a)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) is deemed to be granted unless, within 60 days of the filing of the request, FDA finds that one or more of the bases for denying the request listed at section 575(a)(2) of the FD&C Act applies. FDA has made no such finding in connection with your request, and 60 days have passed since your request was filed. Accordingly, by operation of section 575(a)(2) of the FD&C Act, your request for certification of Nitrogen, NF, as a designated medical gas is deemed to be granted, and you now have in effect an approved new drug application (NDA 212315) for human drug use and an approved new animal drug application (NADA N-141-505) for animal drug use for this gas effective 8/24/2018.

We remind you that if you make any changes to the information in your certification request, such as where the gas is manufactured, how it is manufactured, or changes in applicant information, you will need to submit an updated certifications request to these same application numbers. Send all correspondences concerning this application to the following address:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
5901-B Ammendale Road
Beltsville, MD 20705-1266

Please include the NDA and NADA numbers listed above at the top of the first page of any such communications.

NDA 212315
NADA N-141-505
Page 2

If you have any questions, please contact Michael Folkendt at (301) 796-1670 or by email at michael.folkendt@fda.hhs.gov.

Sincerely,

Charles J. Andres, Ph.D.
Director
Division of Business Information Science and Management
Office of New Animal Drug Evaluation, HFV-180
Center for Veterinary Medicine
FDA

Michael Folkendt
Deputy Director (Acting)
Office of Program and Regulatory Operations
Office of Pharmaceutical Quality
CDER/FDA